Clinical Study
Prediction of Sustained Virological Response to Telaprevir-Based Triple Therapy Using Viral Response within 2 Weeks
Table 5
Predictive values according to significant factors related to sustained virological response.
| | Significant predictive factors | Sensitivity | Specificity | PPV | NPV | Accuracy |
| | Non-NR to prior PEG-IFN and ribavirin | 96% (25/26) | 43% (3/7) | 86% (25/29) | 75% (3/4) | 85% (28/33) | | IL28B major | 77% (20/26) | 86% (6/7) | 95% (20/21) | 50% (6/12) | 79% (26/33) | | Core 70 wild | 60% (15/25) | 86% (6/7) | 94% (15/16) | 38% (6/16) | 66% (21/32) | | No cirrhosis | 65% (17/26) | 86% (6/7) | 94% (17/18) | 40% (6/15) | 70% (23/33) | Hyaluronic acid level
(<346 ng/mL) | 92% (24/26) | 57% (4/7) | 89% (24/27) | 67% (4/6) | 85% (28/33) | Reduction of HCV-RNA at week 1
(>4.36 logIU/mL) | 73% (19/26) | 86% (6/7) | 95% (19/20) | 46% (6/13) | 76% (25/33) | Reduction of HCV-RNA at week 2
(>4.56 logIU/mL) | 77% (20/26) | 86% (6/7) | 95% (20/21) | 50% (6/12) | 79% (26/33) | Reduction of HCV-RNA at week 4
(>6.40 logIU/mL) | 65% (17/26) | 100% (7/7) | 100% (17/17) | 44% (7/16) | 73% (24/33) | | RVR | 77% (20/26) | 71% (5/7) | 91% (20/22) | 45% (5/11) | 76% (25/33) | | Neither the IL28B minor nor core 70 mutant | 80% (20/25) | 71% (5/7) | 91% (20/22) | 50% (5/10) | 78% (25/32) |
|
|
PPV, positive predictive value; NPV, negative predictive value; NR, no response; PEG-IFN, pegylated interferon; IL, interleukin; HCV, hepatitis C virus; RVR, rapid virological response.
|
